Fonterra consumer business sale price jumps to $4.22b
The sale price of Fonterra’s global consumer and associated businesses to the world’s largest dairy company Lactalis has risen to $4.22 billion.
Fonterra’s share price has dropped following a bleak market update on its 2018-19 financial results.
Read: Fonterra is signalling a full-year loss of up to $675 million for 2018-19.
At start of trading day on the NZ Stock Exchange this morning, the share was valued at $3.74 each. By midday the shares had lost 13c or nearly 5% value and hovering around $3.63/share.
Fonterra shares have taken a battering over the past 18 months. In January last year, each share was priced at $6.60. In the last 12 months it has lost 25% of its value.
Fonterra informed the markets this morning that it was bracing for a full-year loss of up to $675 million for 2018-19.
The co-op has also announced that no dividend will be paid for 2018-19; it has also written down $820m to $860m in asset value.
The co-op will announce its full-year results on September 12. However, it’s now clear that the co-op will deliver its second straight annual loss. Last year, the co-op declared its first ever loss of $196m.
Research and healthcare initiatives, leadership and dedication to the sector have been recognised in the 2025 Horticulture Industry Awards.
Virtual fencing and pasture management company Halter says its NZ operations has delivered a profit of $2.8 million after exclusion of notional items.
Manuka honey trader Comvita slumped to a $104 million net loss last financial year, reflecting prolonged market disruption, oversupply and pricing volatility.
The Government has struck a deal with New Zealand's poultry industry, agreeing how they will jointly prepare for and respond to exotic poultry diseases, including any possible outbreak of high pathogenicity avian influenza (HPAI).
The conversion of productive farmland into trees has pretty much annihilated the wool industry.
Thus far in 2025, the Hawke's Bay rescue helicopter crew have completed over 220 missions, resulting in numerous positive patient outcomes.